Your browser doesn't support javascript.
loading
Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1.
Haag, G M; Zoernig, I; Hassel, J C; Halama, N; Dick, J; Lang, N; Podola, L; Funk, J; Ziegelmeier, C; Juenger, S; Bucur, M; Umansky, L; Falk, C S; Freitag, A; Karapanagiotou-Schenkel, I; Beckhove, P; Enk, A; Jaeger, D.
Afiliação
  • Haag GM; Department of Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Germany. Electronic address: GeorgMartin.Haag@med.uni-heidelberg.de.
  • Zoernig I; Department of Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Germany.
  • Hassel JC; Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, Germany.
  • Halama N; Department of Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Germany.
  • Dick J; Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, Germany.
  • Lang N; Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, Germany.
  • Podola L; Translational Immunology, National Center for Tumor Diseases, Heidelberg, Germany.
  • Funk J; Department of Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Germany.
  • Ziegelmeier C; Department of Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Germany.
  • Juenger S; Translational Immunology, National Center for Tumor Diseases, Heidelberg, Germany.
  • Bucur M; Translational Immunology, National Center for Tumor Diseases, Heidelberg, Germany.
  • Umansky L; Translational Immunology, National Center for Tumor Diseases, Heidelberg, Germany.
  • Falk CS; Institute of Transplant Immunology, IFB-Tx, Hannover Medical School, Hannover, Germany.
  • Freitag A; NCT Trial Center, National Center for Tumor Diseases, Heidelberg, Germany.
  • Karapanagiotou-Schenkel I; NCT Trial Center, National Center for Tumor Diseases, Heidelberg, Germany.
  • Beckhove P; Translational Immunology, National Center for Tumor Diseases, Heidelberg, Germany; Regensburg Center for Interventional Immunology, University Hospital Regensburg, Germany.
  • Enk A; Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, Germany.
  • Jaeger D; Department of Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Germany; Clinical Cooperation Unit "Applied Tumor-Immunity", German Cancer Research Center (DKFZ), Heidelberg, Germany.
Eur J Cancer ; 90: 122-129, 2018 02.
Article em En | MEDLINE | ID: mdl-29306769
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Ipilimumab / Antineoplásicos Imunológicos / Melanoma / Proteínas de Membrana / Antígenos de Neoplasias Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Cancer Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Ipilimumab / Antineoplásicos Imunológicos / Melanoma / Proteínas de Membrana / Antígenos de Neoplasias Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Cancer Ano de publicação: 2018 Tipo de documento: Article